gmp
gmp

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Galapagos

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 12, 2020

            Details:

            Scipher and Galapagos will jointly validate a suite of novel IBD targets discovered by Scipher after which Galapagos has the exclusive option to progress up to five targets into further drug discovery and development.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: University of Oxford

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 01, 2020

            Details:

            Celsius will partner with leading academic scientists to access patient tissue samples and apply its proprietary single-cell genomics platform and machine learning capabilities to discover new insights into inflammatory bowel disease (IBD).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Gilead Sciences

            Deal Size: $1,538.0 million Upfront Cash: $38.0 million

            Deal Type: Collaboration April 06, 2020

            Details:

            Second Genome will utilize its proprietary Microbiome Analytics Platform™ to identify novel biomarkers associated with clinical response to Gilead’s investigational medicines.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CDX-7108

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Nestle Health Sciences SA

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 10, 2020

            Details:

            The companies’ new agreement will advance the development of CDX-7108, the lead candidate for a potential treatment of a GI disorder.